Sector News

Sanofi pumps $750M into VC unit to push deeper into biotech investing

January 14, 2023
Life sciences

Sanofi has thrown its financial weight behind its venture capital unit, making a $750 million, multi-year commitment to enable the financier to build on a year in which it backed 10 companies globally.

Sanofi Ventures is a well-established player in the biotech VC space, with its roots dating back to the formation of Sanofi-Genzyme BioVentures in 2011 and beyond that to the establishment of Genzyme Ventures a decade earlier. But Sanofi has largely stayed in the shadows, leaving its venture unit to build out a portfolio without publicly disclosing the details of how it supports the fund.

The release of details of a $750 million commitment changes that. And, as Sanofi CEO Paul Hudson sees things, marks the start of a new phase in the French drugmaker’s relationship with biotech investing.

“As we continue to build our best-in-class pipeline, we are investing in early stage companies that share our ambition of delivering transformative science and digital innovation, Hudson said in a statement. “This capital commitment signals Sanofi’s accelerated ambitions in the venture capital community and our continued desire to collaborate with global innovators in the best interests of patients,” Hudson said in a statement.

The commitment follows a busy 2022 for Sanofi Ventures, in which it participated in financing rounds at companies including streptococcus vaccine developer Minervax, immune disease startup Matchpoint Therapeutics and neurosensory-inflammatory player Escient Pharmaceuticals. Sanofi Ventures kept up its momentum into 2023, starting the new year by co-leading an investment in immuno-oncology startup NextPoint Therapeutics.

The new additions to Sanofi Ventures’ portfolio join a storied list of companies including bluebird bio and Ultragenyx that have received cash from the VC shop. Companies that take up the offer of investment from Sanofi Ventures receive cash, plus the promise of access to Sanofi’s expertise in areas including preclinical and clinical development, regulatory, manufacturing and market access.

By Nick Paul Taylor

Source: fiercebiotech.com

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach